NASDAQ:ADXS Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis $0.03 0.00 (0.00%) As of 10/17/2025 10:38 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Ayala Pharmaceuticals Stock (NASDAQ:ADXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ayala Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.1552-Week Range$0.03▼$0.80Volume1,200 shsAverage Volume4,032 shsMarket Capitalization$1.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ayala Pharmaceuticals is a clinical-stage biotechnology company focused on the development of innovative immunotherapies for cancer. The company’s core technology leverages a proprietary attenuated Listeria monocytogenes–based platform to deliver tumor-associated antigens directly to antigen-presenting cells, stimulating potent T-cell responses. By harnessing the body’s own immune system, Ayala aims to achieve durable anti-tumor activity while maintaining a favorable safety profile. The company’s pipeline comprises several lead candidates targeting a variety of solid tumors. Among these is ADXS-HPV, an immunotherapy designed to treat human papillomavirus–associated cervical cancer, which has advanced into late-stage clinical trials. Ayala is also developing ADXS-NEO, a personalized neoantigen therapy tailored to individual patient tumor profiles, and ADXS-PSA for prostate cancer. These programs reflect the company’s commitment to addressing both virus-driven and mutation-driven malignancies. Founded in the late 2000s under the name Advaxis, the company rebranded as Ayala Pharmaceuticals to underscore its evolution and expanded therapeutic focus. Headquartered in Princeton, New Jersey, Ayala conducts research and clinical operations across the United States and collaborates with academic and research institutions to advance its immunotherapy candidates. The company’s strategic alliances aim to accelerate clinical development and broaden access to its novel therapies. Ayala’s leadership team brings together seasoned executives and scientific experts in oncology, immunology, and biopharmaceutical development. The company remains dedicated to translating its Listeria-based platform into meaningful treatments for patients with hard-to-treat cancers, leveraging its expertise to address unmet medical needs in the global oncology community.AI Generated. May Contain Errors. Read More Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADXS Stock News HeadlinesAyala Pharmaceuticals, Inc. (ADXS) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comRockville's OS Therapies acquires rights to key drugs, eyes FDA approval for cancer therapyFebruary 5, 2025 | bizjournals.comShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.October 19 at 2:00 AM | Brownstone Research (Ad)OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to PipelineJanuary 29, 2025 | businesswire.comAyala unit expands cold storage networkSeptember 4, 2024 | msn.comAyala explores minority stake sale in AC Health, sources sayAugust 1, 2024 | msn.comAyala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting ObligationsMay 9, 2024 | globenewswire.comImmunome: An Oncology Powerhouse In The MakingApril 2, 2024 | seekingalpha.comSee More Headlines ADXS Stock Analysis - Frequently Asked Questions How have ADXS shares performed this year? Ayala Pharmaceuticals' stock was trading at $0.0270 at the beginning of the year. Since then, ADXS shares have increased by 23.3% and is now trading at $0.0333. How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) issued its earnings results on Thursday, September, 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The company had revenue of $0.25 million for the quarter. How do I buy shares of Ayala Pharmaceuticals? Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ayala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Acasti Pharma (ACST), Bristol Myers Squibb (BMY) and Matinas Biopharma (MTNB). Company Calendar Last Earnings9/09/2021Today10/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADXS CIK1100397 Webwww.ayalapharma.com Phone609-452-9813Fax609-452-9818Employees20Year Founded2017Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$3.24 million Price / Sales0.44 Cash FlowN/A Price / Cash FlowN/A Book Value($2.06) per share Price / Book-0.02Miscellaneous Outstanding Shares42,633,000Free Float42,364,000Market Cap$1.42 million OptionableNot Optionable Beta1.22 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ADXS) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.